Table. 1.

Estimated FIH dose parameters for mRNA-3927, mRNA-3705, and mRNA-3210 based on PK/PD modeling

	mRNA-3927	mRNA-3705	mRNA-3210
LNP formulation	SM-86/OL-56	SM-86/OL-56	SM-86/OL-56
Starting dose (mg/kg)	0.3	0.1	0.4
FIH dose species	Pcca−/− (A138T) mouse, Sprague-Dawley rat, cynomolgus monkey	CD1 and Mut−/−;TgINS-CBA-G715V mouse, Sprague-Dawley rat, cynomolgus monkey	C57BL/6 B6.BTRB-PAHenu2+/+ (wild-type) and PAHenu2 mouse, cynomolgus monkey
NOAEL (mg/kg)	3	5	3
Safety relevant species	Sprague-Dawley rat	Sprague-Dawley rat	Sprague-Dawley rat
Safety margin	10	50	7.5

FIH first-in-human, LNP lipid nanoparticle, mRNA messenger RNA, NOAEL no-observed-adverse-effect-limit, PD pharmacodynamic, PK pharmacokinetic.